ViaNautis Bio

Executive Summary

ViaNautis Bio is a UK-based biotechnology company pioneering a next-generation, non-viral delivery platform for genetic medicines. Its core technology, polyNaut® nanovesicles (PNVs), is a modular system designed to precisely deliver a broad range of therapeutic payloads to difficult-to-target cells and tissues, including the central nervous system, lungs, and immune system. The company aims to make cell and gene therapies safer, more effective, shelf-stable, and re-dosable. Founded in 2021 and headquartered in London, ViaNautis has attracted attention for its innovative approach to overcoming key limitations of viral vectors, such as immunogenicity and limited payload capacity. While still in early stages, the platform has potential applications across multiple therapeutic areas, positioning the company as a promising player in the drug delivery space.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round80% success
• Q4 2026Proof-of-Concept Data in CNS Indication60% success
• Q1 2027Strategic Partnership with Major Pharma50% success